

No. 22A902

No. 22A901

IN THE
Supreme Court of the United States

U.S. FOOD & DRUG ADMINISTRATION *et al.*,
Applicants,

v.

ALLIANCE FOR HIPPOCRATIC MEDICINE *et al.*,
Respondents.

DANCO LABORATORIES, L.L.C.,
Applicant,

v.

ALLIANCE FOR HIPPOCRATIC MEDICINE *et al.*,
Respondents.

**BRIEF FOR 253 MEMBERS OF CONGRESS AS *AMICUS CURIAE* IN
SUPPORT OF APPLICATIONS TO STAY THE ORDER ENTERED BY THE
UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF
TEXAS AND FOR AN ADMINISTRATIVE STAY**

Boris Bershteyn
Counsel of Record
One Manhattan West
New York, NY 10001
(212) 735-3000
boris.bershteyn@probonolaw.com

William A. McConagha
Jennifer L. Bragg
Keyawna Griffith
1440 New York Ave NW
Washington, DC 20005

Counsel for Amicus Curiae 253 Members of Congress

A complete list of the 50 U.S. Senators and the 203 Members of the U.S. House of Representatives participating as *amici curiae* is provided as an appendix to the brief. Among them are:

Sen. Charles E. Schumer	Rep. Hakeem Jeffries
Sen. Patty Murray	Rep. Katherine Clark
Sen. Bernard Sanders	Rep. Frank Pallone, Jr.
Sen. Richard J. Durbin	Rep. Jerrold Nadler
Sen. Richard Blumenthal	Rep. Diana DeGette
	Rep. Barbara Lee

TABLE OF CONTENTS

	<u>Page</u>
INTEREST OF <i>AMICI CURIAE</i>	1
SUMMARY OF ARGUMENT	1
ARGUMENT	4
I. Congress Charged Experts at FDA with Evaluating the Safety and Effectiveness of Drugs—Subject Only to Circumscribed Judicial Review	4
II. FDA’s Determination that Mifepristone is Safe and Effective Followed a Thorough and Comprehensive Process Prescribed and Overseen by the Legislative Branch	8
A. The District Court’s Focus On 21 C.F.R. Part 314, Subpart H, Is Misplaced Because FDA’s Authority To Authorize Mifepristone Is Derived From Statutory Authority Under the FDCA, And Any Alleged Defect In The 2000 Approval of Mifepristone Has Been Cured By Subsequent Congressional Action.....	8
B. The Integrity of FDA’s Approval Process Of Mifepristone Has Been Examined and Validated	12
III. A Judicial Stay of FDA’s Post-2015 Regulatory Oversight of Mifepristone Would Profoundly Disrupt the Science-Based, Expert-Driven Process that Congress Designed for Determining Whether Drugs are Safe and Effective	14
IV. Invalidating FDA’s Post-2015 Regulation of Mifepristone Would Reduce Access to Abortion, Exacerbating an Already Significant Reproductive Health Crisis	15
CONCLUSION.....	22
APPENDIX.....	A-1

TABLE OF AUTHORITIES

Page(s)

CASES

Baltimore Gas & Electric Co. v. Natural Resources Defense Council, Inc., 462 U.S. 87 (1983) 5

Dobbs v. Jackson Women’s Health Organization, 142 S. Ct. 2228 (2022) 1, 3, 15, 17, 18, 21

MKB Management Corp. v. Burdick, 855 N.W.2d 31 (N.D. 2014) 7

National Mining Ass’n v. Secretary, U.S. Department of Labor, 812 F.3d 843 (11th Cir. 2016) 5, 15

Planned Parenthood of Southwest & Central Florida v. State, No. 2022 CA 912, 2022 WL 2436704 (Fla. Cir. Ct. July 5, 2022), rev’d on other grounds, 344 So. 3d 637 (Fla. Dist. Ct. App. 2022), review granted, No. SC22-1050, 2023 WL 356196 (Fla. Jan. 23, 2023) 7

Sabine River Authority v. U.S. Department of Interior, 951 F.2d 669 (5th Cir. 1992) 7

Schering Corp. v. FDA, 51 F.3d 390 (3d Cir. 1995) 5

STATUTES

5 U.S.C. § 706(2) 5

18 U.S.C. § 1461 11

21 U.S.C. § 321(p) 2, 4

21 U.S.C. § 355 4, 9

21 U.S.C. § 355(a) 2, 4

21 U.S.C. § 355(b)(1) 5

21 U.S.C. § 355(b)(1)(A)(i) 8, 9

21 U.S.C. § 355(d) 5

21 U.S.C. § 355(e) 14

21 U.S.C. § 355(h) 5

21 U.S.C. § 355-1..... 11

21 U.S.C. § 355-1(a)(1)..... 10

21 U.S.C. § 355-1(a)(1)(B)..... 10

21 U.S.C. § 355-1(a)(1)(C)..... 10

21 U.S.C. § 355-1(a)(1)(E)..... 10

21 U.S.C. § 371..... 9

21 U.S.C. § 371(a) 4

21 U.S.C. § 393(b)(2)(B) 4

Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 to 399i..... 2

Food and Drug Administration Amendments Act of 2007,
 Pub. L. No. 110-85, § 909(b)(1)(A), 121 Stat. 823, 950 11

REGULATIONS

21 C.F.R. § 314.500..... 9

Identification of Drug and Biological Products Deemed to Have Risk
 Evaluation and Mitigation Strategies for Purposes of the Food and
 Drug Administration Amendments Act of 2007, 73 Fed. Reg. 16,313
 (Mar. 27, 2008) 11

New Drug, Antibiotic and Biological Drug Product Applications; Accelerated
 Approval, 57 Fed. Reg. 13,234 (proposed Apr. 15, 1992)..... 10

New Drug, Antibiotic and Biological Drug Product Applications; Accelerated
 Approval, 57 Fed. Reg. 58,942 (Dec. 11, 1992)..... 8, 9

OTHER AUTHORITIES

153 Cong. Rec. 10940 (May 2, 2007) 11

153 Cong. Rec. 11668 (May 9, 2007) 11

Affidavit of Dr. Sharon Liner in Support of Plaintiffs’ Motion, Preterm-
 Cleveland v. Yost, No. A2203203 (Ohio Ct. Com. Pl. filed Sept. 2, 2022)..... 16

Appellants’ Exhibits in Support of Motion for Stay, Alliance Hippocratic
 Medicine v. FDA, No. 23-10362 (5th Cir. April 10, 2023), Dkt. No. 27.. 6, 8, 11,
 12

Chantel Boyens et al., Access to Paid Leave Is Lowest Among Workers with the Greatest Needs, Urban Inst. (July 2022), https://www.urban.org/sites/default/files/2022-07/Access%20to%20Paid%20Leave%20Is%20Lowest%20among%20Workers%20with%20the%20Greatest%20Needs.pdf	20
Brief of Amicus Curiae Doctors for America, Alliance for Hippocratic Medicine v. U.S. Food & Drug Administration, No. 2:22-cv-00223-Z (N. D. Tex. Feb. 13, 2023), Dkt. No. 99	17
Cong. Budget Off., Research and Development in the Pharmaceutical Industry (2021), https://www.cbo.gov/system/files/2021-04/57025-Rx-RnD.pdf	15
Ctr. for Drug Evaluation & Rsch., U.S. Food & Drug Admin., Application No. 20-687, Medical Reviews (1999), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20687_Mifepristone_medr_P1.pdf	9
Ctr. for Drug Evaluation & Rsch. (CDER), Drug and Biologic Restricted Distribution Approvals As of June 30, 2018, FDA: U.S. Food & Drug Admin, https://www.fda.gov/media/115040/download (last visited Apr. 11, 2023)	10
Eugene Declercq et al., The U.S. Maternal Health Divide: The Limited Maternal Health Services and Worse Outcomes of States Proposing New Abortion Restrictions, Commonwealth Fund (Dec. 14, 2022), https://www.commonwealthfund.org/publications/issue-briefs/2022/dec/us-maternal-health-divide-limited-services-worse-outcomes	19, 21
Ioannis T. Farmakis et al., Maternal Mortality Related to Pulmonary Embolism in the United States, 2003-2020, 5 A.M. J. Obstetrics & Gynecology Maternal-Fetal Med. 100754 (2023).....	17
2 FDA Staff Medical Guides—Delegations of Authority, SMG 1410.10 (Feb. 22, 2023) (Delegations of Authority to the Commissioner of Food and Drugs), https://www.fda.gov/media/81983/download	4
Diana Greene Foster, The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having—or Being Denied—an Abortion (2021)	20
Diana Greene Foster et al., Socioeconomic Outcomes of Women Who Receive and Women Who Are Denied Wanted Abortions in the United States, 108 Am. J. Pub. Health 407 (2018)	20

Karen Brooks Harper, Wealth Will Now Largely Determine Which Texans Can Access Abortion, <i>Tex. Trib.</i> (June 24, 2022), https://www.texastribune.org/2022/06/24/texas-abortion-costs/	20
Donna L. Hoyert, Maternal Mortality Rates in the United States, 2020, CDC (Feb. 23, 2022), https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2020/maternal-mortality-rates-2020.htm	21
Donna L. Hoyert, Maternal Mortality Rates in the United States, 2021, CDC (Mar. 16, 2023), https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.htm	20
Hypertension, World Health Org., https://www.who.int/health-topics/hypertension#tab=tab_1 (last visited Apr. 11, 2023)	10
Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation, FDA: U.S. Food & Drug Admin. (Mar. 23, 2023), https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation	8
Irritable Bowel Syndrome (IBS), NHS Inform, https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/irritable-bowel-syndrome-ibs (last visited Apr. 11, 2023)	10
Rachel K. Jones et al., Medication Abortion Now Accounts for More Than Half of All US Abortions, <i>Guttmacher Inst.</i> (Feb. 24, 2022), https://www.guttmacher.org/article/2022/02/medication-abortion-now-accounts-more-half-all-us-abortions	18
Marielle Kirstein et al., 100 Days Post-Roe: At Least 66 Clinics Across 15 US States Have Stopped Offering Abortion Care, <i>Guttmacher Inst.</i> (Oct. 6, 2022), https://www.guttmacher.org/2022/10/100-days-post-roe-least-66-clinics-across-15-us-states-have-stopped-offering-abortion-care	16
Jessica Beaman et al., Medication to Manage Abortion and Miscarriage, 35 <i>J. Gen. Intern. Med.</i> 2398 (2020).....	18
Jennifer Ko, What the FDA Can Teach Us About Regulatory Excellence, <i>Regulatory Rev.</i> (Jan. 16, 2018), https://www.theregreview.org/2018/01/16/fda-teach-regulatory-excellence/	4

Michelle Meadows, Promoting Safe and Effective Drugs for 100 Years, FDA Consumer: The Centennial Edition (Jan.-Feb. 2006), https://www.fda.gov/files/Promoting-Safe-and-Effective-Drugs-for-100-Years-%28download%29.pdf	4
Mifepristone U.S. Post-Marketing Adverse Events Summary through 06/30/2022, U.S. Food & Drug Admin., https://www.fda.gov/media/164331/download (last visited Apr. 11, 2023)	13
Nat'l Acads. of Scis., Eng'g & Med., The Safety and Quality of Abortion Care in the United States (2018), http://nap.edu/24950	6
Plaintiffs' Original Petition for Declaratory Judgment and Application for Permanent Injunction, <i>Zurawski v. State</i> , No. D-1-GN-23-000968 (Tex. Dist. Ct. filed Mar. 6, 2023)	16, 17
Order Granting Motion for Clarification, <i>Washington v. FDA</i> , No. 1:23-cv-3026 (E.D. Wash. April 13, 2023), Dkt. No. 91	7
Rosalyn Schroeder et al., Trends in Abortion Care in the United States, 2017-2021, <i>Advancing New Standards in Reprod. Health</i> , U.C.S.F. (2022)	19
Frances Stead Sellers & Fenit Nirappil, Confusion Post-Roe Spurs Delays, Denials for Some Lifesaving Pregnancy Care, <i>Wash. Post</i> (July 16, 2022), https://www.washingtonpost.com/health/2022/07/16/abortion-miscarriage-ectopic-pregnancy-care/	16
U.S. Dep't of Health & Hum. Servs., Approved Drug Products with Therapeutic Equivalence Evaluations (43rd ed. 2023), https://www.fda.gov/media/71474/download	14
U.S. Dep't of Just., Off. of Legal Counsel, Application of the Comstock Act to the Mailing of Prescription Drugs That Can Be Used for Abortions (Dec. 23, 2022), https://www.justice.gov/d9/opinions/attachments/2023/01/03/2022-12-23_-_comstock_act_1.pdf	11
U.S. Gov't Accountability Off., GAO-08-751, Food and Drug Administration: Approval and Oversight of the Drug Mifeprex (2008), https://www.gao.gov/assets/gao-08-751.pdf	12
U.S. Gov't Accountability Off., GAO-18-292, Food and Drug Administration: Information on Mifeprex Labeling Changes and Ongoing Monitoring Efforts (2018), https://www.gao.gov/assets/gao-18-292.pdf	13

Jessica Valenti, I Write About Post-Roe America Every Day. It's Worse Than You Think, N.Y. Times (Nov. 5, 2022), <https://www.nytimes.com/2022/11/05/opinion/election-abortion-roe-women.html>..... 17

Rosemary Westwood, Bleeding and in Pain, She Couldn't Get 2 Louisiana ERs to Answer: Is It a Miscarriage?, WGCU (Dec. 29, 2022), <https://news.wgcu.org/2022-12-29/bleeding-and-in-pain-she-couldnt-get-2-louisiana-ers-to-answer-is-it-a-miscarriage> 18

What Are the Risks of Preeclampsia & Eclampsia to the Mother?, Nat'l Insts. of Health, <https://www.nichd.nih.gov/health/topics/preeclampsia/conditioninfo/risk-mother> (last updated Nov. 19, 2018)..... 17

Katherine O'Connell White, POV: Overturning Roe v. Wade Will Worsen Health Inequities in All Reproductive Care, BU Today (June 24, 2022), <https://www.bu.edu/articles/2022/overturning-roe-v-wade-will-worsen-health-inequities/> 19

INTEREST OF *AMICI CURIAE*¹

Amici curiae are 253 Members of Congress—50 Senators and 203 Members of the House of Representatives. (See Appendix for List of *Amici*.) *Amici* have a special interest in both upholding the Constitution’s separation of powers—among other things, by ensuring that federal administrative agencies are able to faithfully exercise the authorities Congress delegated to them by statute without undue judicial interference—and protecting the physical health and safety of their constituents.

Amici believe that the district court’s stay of FDA’s September 28, 2000 approval of mifepristone and of other subsequent challenged agency actions has no basis in law, threatens the Congressionally mandated drug approval process, and poses a serious health risk to pregnant individuals by making abortion more difficult to access—when access has already been seriously eroded in the aftermath of *Dobbs v. Jackson Women’s Health Organization*. Accordingly, *Amici* respectfully urge this Court to grant the applications and stay the district court’s order in full, and also grant an immediate administrative stay while this Court considers the applications.

SUMMARY OF ARGUMENT

For the last century, a statutory scheme designed by Congress has assured the safety and effectiveness of the drugs available in the United States. At its core resides the application of scientific standards by agency experts. In 1938, Congress enacted

¹ Pursuant to Rule 37.6 of the Rules of this Court, amici state that no counsel for a party wrote this brief in whole or in part. No party, party’s counsel or any person other than the *amicus curiae*, their members, or their counsel contributed money that was intended to finance the preparation or submission of this brief.

the Federal Food, Drug, and Cosmetic Act (“FDCA”), which established the foundations for the modern regulation of our drug supply. *See* 21 U.S.C. §§ 321(p), 355(a). Congress designated the U.S. Food and Drug Administration (“FDA”) as the expert federal agency with authority to review and approve drug applications, including subsequent changes to those applications. While Congress permitted some judicial review of FDA’s approval decisions, it did not invite federal courts to substitute their judgment for the expert conclusions of FDA’s scientists.

Here, FDA’s determination that mifepristone is safe and effective is based on a thorough and comprehensive review process prescribed and overseen by the legislative branch. Since mifepristone’s initial approval in 2000, FDA has repeatedly and consistently affirmed that the medication is safe and effective for its approved conditions of use. FDA’s process and conclusions have been validated by both Congress and the Government Accountability Office—and by the lived experience of over 5 million patients who have used the drug in the United States. And, as with all drugs, FDA continued to closely monitor the post-marketing safety data on mifepristone.

By maintaining the district court’s stay of mifepristone’s current, FDA-approved conditions of use, the Fifth Circuit has disrupted the longstanding statutory framework and erroneously countenanced an extraordinary remedy. Decades after FDA’s initial approval—yet somehow in an emergency posture—the district court intruded into FDA’s drug approval process, casting a shadow of uncertainty over its decisions. The perils of this unwarranted judicial intervention into science-based

determinations can hardly be overstated. Researchers, health care providers, and patients suffering from a range of medical conditions rely on the integrity and stability of the rigorous science-based drug approval process. The specter of precipitous judicial meddling therefore threatens access to life-improving and lifesaving drugs.

More immediately, the misguided stay of mifepristone's current FDA-approved conditions of use will reduce access to abortion, exacerbating an already significant reproductive health crisis. Although the district court styled its relief as "less drastic," it is not apparent that its consequences are less disruptive than those of a mandatory injunction. Since the Supreme Court's decision in *Dobbs v. Jackson Women's Health Organization*, abortion has become inaccessible in much of the United States. The resulting delays and denials of care have already had baleful effects on the health of pregnant individuals, for some of whom pregnancy is a life-threatening condition, regardless of their desire to carry their fetus to term. The Fifth Circuit's order would exacerbate these adverse health outcomes by limiting access to the most common method of early abortion—a two drug regimen of mifepristone and misoprostol.

Therefore, emergency relief from the order is necessary to mitigate the imminent harm facing members of the public, many of whom rely on the availability of mifepristone for reproductive care—and many more of whom rely on the integrity of FDA's drug approval process for continued access to life-improving and lifesaving drugs. Congress intended to—and did—vest authority in FDA to evaluate and ensure

the safety and efficacy of drugs in the United States, and *Amici* call on this Court to give due weight to that intent.

ARGUMENT

I. CONGRESS CHARGED EXPERTS AT FDA WITH EVALUATING THE SAFETY AND EFFECTIVENESS OF DRUGS—SUBJECT ONLY TO CIRCUMSCRIBED JUDICIAL REVIEW

Congress has designed a system for assuring the safety and effectiveness of the drugs available in the United States—a system that became the envy of the world.² At the core of that system is the expert application of scientific standards. In 1938, Congress enacted a landmark statute, the FDCA, which established the foundations for the modern regulation of our drug supply. *See* 21 U.S.C. §§ 321(p), 355(a). Since 1962, Congress has required that drugs be shown to be safe and effective for their intended use before they can be sold in the United States. *See* 21 U.S.C. § 355; *see also id.* § 393(b)(2)(B).

FDA is the expert agency charged by Congress with reviewing and approving drug applications and any subsequent changes to those applications.³ In accordance

² *See* Jennifer Ko, *What the FDA Can Teach Us About Regulatory Excellence*, *Regulatory Rev.* (Jan. 16, 2018), <https://www.theregreview.org/2018/01/16/fda-teach-regulatory-excellence/>; *see also* Michelle Meadows, *Promoting Safe and Effective Drugs for 100 Years*, *FDA Consumer: The Centennial Edition* (Jan.-Feb. 2006).

³ *See* 21 U.S.C. § 371(a) (“The authority to promulgate regulations for the efficient enforcement of this chapter [21 U.S. Code ch. 9 (the FDCA)] . . . is vested in the Secretary [of Health and Human Services].”). The Secretary of Health and Human Services (“the Secretary”) has in turn delegated all functions vested in the Secretary under the FDCA to the Commissioner. *See* 2 FDA Staff Medical Guides—Delegations of Authority, SMG 1410.10, para. 1(A)(1) (Feb. 22, 2023)
(cont'd)

with congressional design, a team of physicians, statisticians, chemists, pharmacologists, and other scientific experts reviews each New Drug Application (“NDA”) submitted to the agency and assesses all relevant data in light of the proposed labeling and intended use of the drug.⁴ The agency must approve an application if, among other requirements, it has concluded that the drug is safe and effective under the conditions of use prescribed, recommended or suggested in the proposed labeling.⁵

FDCA’s review provisions do not invite the courts to substitute their judgment for the expert assessment of FDA scientists, but to treat their “findings . . . as to the facts, if supported by substantial evidence,” as “conclusive.” 21 U.S.C. § 355(h); *see also Schering Corp. v. FDA*, 51 F.3d 390, 399 (3d Cir. 1995) (“[J]udgments as to what is required to ascertain the safety and efficacy of drugs fall squarely within the ambit of FDA’s expertise and merit deference from us.”); 5 U.S.C. § 706(2) (limiting scope of review to certain circumscribed grounds); *Balt. Gas & Elec. Co. v. Nat. Res. Def. Council, Inc.*, 462 U.S. 87, 103 (1983) (“When examining [an expert agency’s] scientific determination, as opposed to simple findings of fact, a reviewing court must generally be at its most deferential.”); *Nat’l Mining Ass’n v. Sec’y, U.S. Dep’t of Lab.*, 812 F.3d 843, 866 (11th Cir. 2016) (it is appropriate for reviewing courts to “give an

(Delegations of Authority to the Commissioner of Food and Drugs), <https://www.fda.gov/media/81983/download>.

⁴ *See* 21 U.S.C. § 355(b)(1).

⁵ *See* 21 U.S.C. § 355(d).

extreme degree of deference to the agency when it is evaluating scientific data within its technical expertise”; “[t]o do otherwise puts [a] court in the unenviable—and legally untenable—position of making for itself judgments entrusted by Congress to [the expert agency]” (citation omitted). Indeed, the district court’s order appears to be the very first time in FDA’s history that a court has stayed the approval of a widely marketed drug over the agency’s objection.

Here, rather than affording any deference to FDA, the district court appears to have second-guessed FDA’s expert determinations with cherry-picked anecdotes and studies, and on that basis, imposed a remedy that could significantly upend the status quo. Appellants’ Exhibits in Supp. of Mot. for Stay at Add. 44-45, *Alliance Hippocratic Medicine v. FDA*, No. 23-10362 (5th Cir. April 10, 2023), Dkt. No. 27 (hereinafter, “Add.”) (asserting that “chemical abortion drugs do not provide a meaningful therapeutic benefit over surgical abortion.”); *id.* at 48 (claiming that surgical abortion is a far safer procedure); *id.* at 52 (relying on “myriad stories and studies brought to the Court’s attention”); *id.* at 57-58 (admitting the court does not have exact numbers and is relying on compounding assumptions). The National Academies of Sciences, Engineering and Medicine have concluded that much of the published literature on the supposed negative effects of abortion (such as that relied upon by the district court) “fails to meet scientific standards for rigorous, unbiased research.”⁶ Numerous courts have rejected the expert testimony of the physicians

⁶ Nat’l Acads. of Scis., Eng’g & Med., *The Safety and Quality of Abortion Care in the United States* 152 (2018), <http://nap.edu/24950>.

whose submissions the district court accepted at face value.⁷ Even when “conflicting evidence is before the agency”—which was not the case here—“the agency and not the reviewing court has the discretion to accept or reject from the several sources of evidence.” *Sabine River Auth. v. U.S. Dep’t of Interior*, 951 F.2d 669, 678 (5th Cir. 1992).

For decades, the federal judiciary has respected Congress’s delegation of the drug approval process to FDA’s scientists and experts.⁸ While courts have, on occasion, held against FDA on issues related to the market exclusivity that is afforded to a drug sponsor by the statute, it is an extraordinary and unprecedented step for the district court to invalidate on substantive grounds—and over FDA’s objection—a longstanding approval for a drug with a history of safe and effective use. This Court should stay the entirety of that aberrant decision pending appellate review.

⁷ See, e.g., *MKB Mgmt. Corp. v. Burdick*, 855 N.W.2d 31, 68 (N.D. 2014) (per curiam) (rejecting testimony of Dr. Harrison as lacking “scientific support”); *Planned Parenthood of Sw. & Cent. Fla. v. State*, No. 2022 CA 912, 2022 WL 2436704, at *13 (Fla. Cir. Ct. July 5, 2022) (rejecting testimony of Dr. Skop, who “provided no credible scientific basis for her disagreement with recognized high-level medical organizations in the United States”), *rev’d on other grounds*, 344 So. 3d 637 (Fla. Dist. Ct. App. 2022).

⁸ Different federal courts have now issued contradicting orders to FDA with respect to their regulation of mifepristone. See Order Granting Mot. for Clarification, *Washington v. FDA*, No. 1:23-cv-3026 (E.D. Wash. April 13, 2023), Dkt. No. 91 (enjoining FDA defendants from “altering the status quo and rights as it relates to the availability of Mifepristone” under the current operative REMS “in Plaintiff States and the District of Columbia”). These contradicting orders further reinforce that Congress, for good reasons, conferred the authority to regulate drugs on FDA, and not on the judiciary.

II. FDA'S DETERMINATION THAT MIFEPRISTONE IS SAFE AND EFFECTIVE FOLLOWED A THOROUGH AND COMPREHENSIVE PROCESS PRESCRIBED AND OVERSEEN BY THE LEGISLATIVE BRANCH

More than twenty years ago, FDA approved mifepristone, determining that it is safe and effective for the medical termination of intrauterine pregnancy under the conditions set forth in the FDA-approved prescribing information. Add. 181 (Approval of NDA for mifepristone, Sept. 28, 2000); *see also* 21 U.S.C. § 355(b)(1)(A)(i), (c)(1)(A), (d). Since then, FDA has repeatedly and consistently affirmed that mifepristone is safe and effective for its approved conditions of use.⁹

A. The District Court's Focus On 21 C.F.R. Part 314, Subpart H, Is Misplaced Because FDA's Authority To Authorize Mifepristone Is Derived From Statutory Authority Under the FDCA, And Any Alleged Defect In The 2000 Approval of Mifepristone Has Been Cured By Subsequent Congressional Action

The district court's focus on 21 C.F.R. Part 314, Subpart H, ignores FDA's longstanding interpretation of that regulation. In 1992, FDA lawfully promulgated Subpart H, in accordance with the APA, to help assure the safety and effectiveness of products for use in the United States. *See* 57 Fed. Reg. 58,942, 58,958 (Dec. 11, 1992) (promulgating Subpart H). Subpart H applies to federal regulations for certain new drugs "studied for their safety and effectiveness in treating serious or life-threatening illnesses" that "provide meaningful therapeutic benefit to patients over

⁹ *See Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation*, FDA: U.S. Food & Drug Admin. (Mar. 23, 2023), <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation>.

existing treatments.” 21 C.F.R. § 314.500. This was an entirely appropriate and proper exercise of authority, consistent with Section 701 of the FDCA, 21 U.S.C. § 371, which expressly authorizes FDA to promulgate regulations for the efficient enforcement of the FDCA.¹⁰

However, FDA’s authority to approve mifepristone stemmed from Section 505 of the FDCA, 21 U.S.C. § 355, not from 21 C.F.R. Part 314, Subpart H. Prior to marketing a new drug, a sponsor must file an NDA pursuant to Section 505(b) of the FDCA, and must demonstrate that the drug is safe and effective for the proposed indication. 21 U.S.C. § 355(b)(1)(A)(i).

When FDA approved mifepristone in 2000, it reviewed data from two “prospective, open-label, multicenter clinical trials” in the United States involving over two thousand patients,¹¹ as well as expert advice from members of the FDA Reproductive Health Drugs Advisory Committee.¹² Moreover, the agency’s determination was consistent with its long-standing construction of the scope of these regulations and similar regulatory programs to cover drugs designed for “conditions” as well as illnesses and diseases. In the final rule, FDA explained that Subpart H was available for serious or life-threatening “conditions,” whether or not they were understood colloquially to be “illnesses.” 57 Fed. Reg. 58,942, 58,946 (Dec. 11, 1992)

¹⁰ See *supra* note 3.

¹¹ See Ctr. for Drug Evaluation & Rsch., U.S. Food & Drug Admin., Application No. 20-687, Medical Reviews 6-20 (1999).

¹² See *id.* at 21.

(explaining that “FDA’s reference to depression and psychoses” in its preamble to the proposed rule “was intended to give examples of conditions or diseases that can be serious for certain populations or in some or all of their phases”); *see also* 57 Fed. Reg. 13,234, 13,235 (proposed Apr. 15, 1992) (preamble).¹³

Moreover, any alleged defect in the original approval of mifepristone in 2000 was cured in 2007, when Congress gave FDA the authority to require a risk evaluation and mitigation strategy (“REMS”) in circumstances when FDA determined that such a strategy is “necessary to ensure that the benefits of the drug outweigh the risks.”¹⁴ 21 U.S.C. § 355-1(a)(1). When Congress codified the restricted use and distribution provisions of Subpart H in 2007 through the REMS program, it applied the new REMS framework to drugs for a “disease or *condition*.”¹⁵ When

¹³ *See also* Ctr. for Drug Evaluation & Rsch. (CDER), *Drug and Biologic Restricted Distribution Approvals as of June 30, 2018*, FDA: U.S. Food & Drug Admin, <https://www.fda.gov/media/115040/download> (last visited Apr. 11, 2023) (listing drugs which treat, *inter alia*, pulmonary hypertension and Irritable Bowel Syndrome (IBS)). Both hypertension and IBS are colloquially known as “conditions.” *See Irritable Bowel Syndrome (IBS)*, NHS Inform, <https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/irritable-bowel-syndrome-ibs> (last visited Apr. 11, 2023); *Hypertension*, World Health Org., https://www.who.int/health-topics/hypertension#tab=tab_1 (last visited Apr. 11, 2023).

¹⁴ Where FDA has determined that a REMS is necessary, the sponsor must submit an application along with a proposed REMS. In making a determination of whether the benefits of the drug outweigh its risks with REMS, FDA shall consider factors including the “seriousness of the disease or condition” to be treated and the “seriousness of any known or potential adverse events that may be related to the drug.” 21 U.S.C. § 355-1(a)(1)(B), (E). Through this process, mifepristone has been subjected to exacting scrutiny and review.

¹⁵ 21 U.S.C. § 355-1(a)(1)(B), (C) (emphasis added).

Congress enacted this REMS provision, it “deemed” drugs with restrictions of distribution under Subpart H, including mifepristone, to have an effective REMS. Pub. L. No. 110-85, § 909(b)(1)(A). Congress was well aware that mifepristone would be included under that provision when it took this action, and it made no exception for it.¹⁶

In 2011, FDA took the step of implementing the REMS for mifepristone under express statutory authority in section 505-1 of the FDCA, 21 U.S.C. § 355-1. FDA had announced several years earlier that mifepristone would require submission of a REMS application. *See* Identification of Drug and Biological Products, 73 Fed. Reg. 16,313, 16,314 tbl. 1 (Mar. 27, 2008). Subsequently, a REMS application for mifepristone was submitted on September 17, 2008, and FDA approved the application on June 8, 2011. Add. 769. By virtue of FDA’s approval of REMS for mifepristone under its express statutory authority, any alleged defect in the prior approval process for mifepristone was affirmatively cured.¹⁷

¹⁶ *See* 153 Cong. Rec. 11668 (May 9, 2007) (statement of Sen. Coburn); 153 Cong. Rec. 10940 (May 2, 2007) (statement of Sen. DeMint).

¹⁷ The district court also misapplied the Comstock Act, 18 U.S.C. § 1461, erroneously ignoring the Department of Justice’s well-reasoned opinion. *See generally* U.S. Dep’t of Just., Off. of Legal Counsel, *Application of the Comstock Act to the Mailing of Prescription Drugs That Can Be Used for Abortions* 46 Op. O.L.C. ___ (Dec. 23, 2022) (concluding that Congress’s repeated actions ratified the well-established judicial construction that the statute did not prohibit the mailing of items designed to produce abortion unless the sender intended them to be used unlawfully). That opinion correctly notes that, in enacting the REMS provision in 2007, Congress acted “in a manner consistent with the understanding that the Comstock Act does not categorically prohibit” the distribution of drugs intended to induce abortions by mail or common carrier. *Id.* at 14.

B. The Integrity of FDA’s Approval Process Of Mifepristone Has Been Examined and Validated

The integrity of FDA’s approval process for mifepristone, including actions after the 2000 approval, has been examined before—and found to be sound. In 2008, the U.S. Government Accountability Office (GAO), an independent, non-partisan agency, conducted an extensive audit of mifepristone’s 2000 approval, concluding it was “generally consistent with the approval processes for the other . . . Subpart H restricted drugs.” GAO-08-751, *Approval and Oversight of the Drug Mifeprex* at 6 (2008).¹⁸ The GAO also noted that, when it came to post-market oversight of mifepristone, “FDA has routinely reviewed the available information on reported adverse events” from a range of sources and then, “working with the drug’s sponsor, has taken a variety of steps . . . to address safety concerns.”¹⁹ Notably, in conducting its study, the GAO “interviewed FDA officials and external stakeholders who had access to technical information or had conducted analyses” concerning the drug.²⁰ The GAO report considered many of the same concerns raised by plaintiffs in this case fifteen years later.

In 2016, after approving a REMS for mifepristone, FDA approved a supplemental NDA. Add. 768-75. In 2018, the GAO reviewed this 2016 approval, and

¹⁸ The report was prepared at the request of three Republican members of Congress during the Bush administration: Senator Enzi, Senator DeMint and Representative Bartlett. See GAO-08-751, *supra*, at 1.

¹⁹ *Id.* at 38, 41.

²⁰ *Id.* at 4.

after evaluating 62 studies and articles that supported the efficacy of the proposed labeling changes as well as safety information and adverse event data, concluded FDA “followed its standard review process when it approved the [2016 supplemental new drug application] and revised labeling.”²¹ The report further found that “FDA has conducted a variety of monitoring activities and these have not identified significant concerns with the safety and use of [mifepristone], in accordance with its approved REMS.”²²

FDA has repeatedly demonstrated that its approval of mifepristone is based on a rigorous review of scientific data and literature supporting the safety and efficacy of the drug, which has been validated by the decades of experience of many Americans who, in consultation with their health care providers, have chosen to use mifepristone for a medication abortion.²³

²¹ U.S. Gov’t Accountability Off., GAO-18-292, Information on Mifeprex Labeling Changes and Ongoing Monitoring Efforts cover pg. (2018); *see id.* at 11-16.

²² *Id.* at cover pg.

²³ *See Mifepristone U.S. Post-Marketing Adverse Events Summary through 06/30/2022* at 1, U.S. Food & Drug Admin., <https://www.fda.gov/media/164331/download> (last visited Apr. 11, 2023) (“The estimated number of women who have used mifepristone in the U.S. for medical termination of pregnancy through the end of June 2022 is approximately 5.6 million women.”).

III. A JUDICIAL STAY OF FDA'S POST-2015 REGULATORY OVERSIGHT OF MIFEPRISTONE WOULD PROFOUNDLY DISRUPT THE SCIENCE-BASED, EXPERT-DRIVEN PROCESS THAT CONGRESS DESIGNED FOR DETERMINING WHETHER DRUGS ARE SAFE AND EFFECTIVE

The consequences of the Fifth Circuit's decision could extend far beyond mifepristone, for it undermines the science-based, expert-driven process that Congress designed for determining whether drugs are safe and effective. By permitting the district court to disrupt FDA's current regulation of mifepristone, the Fifth Circuit has countenanced judicial interference that erroneously substitutes the district court's judgment for FDA's scientific determination.

As a result, the Fifth Circuit's order undermines the well-established statutory and regulatory framework for the approval and regulation of new drugs and the due process generally accorded to drug marketing application holders by statute.²⁴ Its perilous consequences reach far beyond mifepristone. Providers and patients rely on the availability of thousands of FDA-approved drugs to treat or manage a range of medical conditions, including asthma, HIV, infertility, heart disease, diabetes, and more.²⁵ Moreover, the prospect of courts second-guessing FDA's rigorous drug safety and effectiveness determinations will disrupt industry expectations and could chill pharmaceutical research and development. "Developing new drugs is a costly and

²⁴ Section 505(e) of the FDCA allows for withdrawal of approval of an application with respect to any drug under the section only "after due notice and opportunity for hearing to the applicant." 21 U.S.C. § 355(e).

²⁵ See generally U.S. Dep't of Health & Hum. Servs., *Approved Drug Products with Therapeutic Equivalence Evaluations* (43rd ed. 2023), <https://www.fda.gov/media/71474/download>.

uncertain process,” and only about 12 percent of drugs entering clinical trials are approved by FDA.²⁶ Were each court to take the “legally untenable . . . position of making for itself judgments entrusted by Congress to” FDA, *Nat’l Mining Ass’n*, 812 F.3d at 866, the unpredictability of piecemeal judicial intervention would upend industry expectations, dampening incentives for companies to incur the research and development costs necessary to develop new drugs. Consequently, patient access to life-improving and potentially lifesaving new drugs will suffer, and public interest strongly favors preserving the integrity of FDA’s drug-approval and review process.

IV. INVALIDATING FDA’S POST-2015 REGULATION OF MIFEPRISTONE WOULD REDUCE ACCESS TO ABORTION, EXACERBATING AN ALREADY SIGNIFICANT REPRODUCTIVE HEALTH CRISIS

In the aftermath of the Supreme Court’s decision in *Dobbs v. Jackson Women’s Health Organization*, abortion has become inaccessible in much of the United States. Abortion is banned, with extremely limited exceptions for life-endangerment, in 12 states, and access is severely restricted in an additional 12 states.²⁷ Approximately 22 million women of childbearing age, representing almost one third of the total population of women ages 15 to 49—in addition to other people who may not identify as women but are capable of becoming pregnant and may need an abortion—now live

²⁶ Cong. Budget Off., Research and Development in the Pharmaceutical Industry at 2 (2021).

²⁷ See *After Roe Fell: Abortion Laws by State*, Ctr. for Reprod. Rts., <https://reproductiverights.org/maps/abortion-laws-by-state/> (last visited Mar. 13, 2023).

in states where abortion is entirely unavailable or severely restricted.²⁸ At least 66 clinics across 15 states have stopped offering abortion care.²⁹ (Prior to June 24, 2022, those same 15 states had a total of 79 clinics that offered abortion care; now, there are only 13 such clinics, all located in Georgia.³⁰) Travel time and wait time to obtain abortion care have increased significantly across the United States. The shortage of providers has also stretched the capacity of clinics in states where abortion remains legal.³¹

The resulting delays and denials of care have already dangerously affected health outcomes for pregnant individuals. Some individuals report being forced to forgo cancer treatment,³² while others report developing sepsis,³³ being left bleeding for days after an incomplete miscarriage,³⁴ enduring the risk of rupture due to ectopic

²⁸ Marielle Kirstein et al., *100 Days Post-Roe: At Least 66 Clinics Across 15 US States Have Stopped Offering Abortion Care*, Guttmacher Inst. (Oct. 6, 2022), <https://www.guttmacher.org/2022/10/100-days-post-roe-least-66-clinics-across-15-us-states-have-stopped-offering-abortion-care>.

²⁹ *Id.*

³⁰ *Id.*

³¹ *Id.*

³² Affidavit of Dr. Sharon Liner in Support of Plaintiffs' Motion at 4-5, *Preterm-Cleveland v. Yost*, No. A2203203 (Ohio Ct. Com. Pl. filed Sept. 2, 2022).

³³ Complaint ¶¶ 17-25, *Zurawski v. Texas*, No. D-1-GN-23-000968 (Tex. Dist. Ct. filed Mar. 6, 2023); *see also id.* at 1 (plaintiffs were denied necessary and potentially lifesaving obstetrical care because medical professionals throughout the state feared liability under Texas's abortion bans).

³⁴ Frances Stead Sellers & Fenit Nirappil, *Confusion Post-Roe Spurs Delays, Denials for Some Lifesaving Pregnancy Care*, Wash. Post (July 16, 2022), *(cont'd)*

pregnancy or being forced to continue carrying a fetus diagnosed with a lethal fetal anomaly such as anencephaly.³⁵ For some individuals, pregnancy is a life-threatening condition, regardless of their desire to carry their fetus to term.³⁶ Since *Dobbs*, numerous individuals have been left struggling to access the essential health care they need.³⁷ Reports from doctors and journalists highlight the increasing importance of mifepristone for reproductive health care in *Dobbs*' wake:

- One doctor who had “to stop providing abortion care to patients in Wisconsin for the past six months” observes “further difficulties for patients in rural settings.” Rural patients “are now being forced to birth, so the risks of bleeding and poor fetal and maternal outcomes have significantly risen. Mifepristone is vital to providing safe care for early pregnancy loss.”³⁸
- Another doctor recounts a patient who was raped when she was actively planning for pregnancy. The soonest a paternity test could be conducted was at 7 weeks gestation, while Texas, where the patient lived, had banned abortion after 6 weeks. The patient could not afford to travel out of state

<https://www.washingtonpost.com/health/2022/07/16/abortion-miscarriage-ectopic-pregnancy-care/>.

³⁵ See Complaint ¶¶ 82-94, *Zurawski*, *supra* note 33.

³⁶ See, e.g., Ioannis T. Farmakis et al., Maternal Mortality Related to Pulmonary Embolism in the United States, 2003-2020, 5 A.M. J. Obstetrics & Gynecology Maternal-Fetal Med. 100754 (2023); What Are the Risks of Preeclampsia & Eclampsia to the Mother?, Nat'l Insts. of Health, <https://www.nichd.nih.gov/health/topics/preeclampsia/conditioninfo/risk-mother> (last updated Nov. 19, 2018).

³⁷ See Jessica Valenti, *I Write About Post-Roe America Every Day. It's Worse Than You Think*, N.Y. Times (Nov. 5, 2022), <https://www.nytimes.com/2022/11/05/opinion/election-abortion-roe-women.html>.

³⁸ Brief of *Amicus Curiae* Doctors for America at 6-7, *All. for Hippocratic Med. v. U.S. Food & Drug Admin.*, No. 2:22-cv-00223-Z (N. D. Tex. Feb. 13, 2023), Dkt. No. 99.

for termination, and had to seek a medication abortion before her sixth week.³⁹

- A woman residing in Louisiana, where all abortion (including in cases of rape and incest) has been banned after *Dobbs*, was refused treatment for her miscarriage when she was between 10 and 11 weeks pregnant. When asked whether treatment was available to alleviate her pain and speed up the process, the doctor replied: “We’re not doing that now.”⁴⁰ Mifepristone is part of standard treatment to manage early pregnancy loss.⁴¹

These examples bespeak a broader public health crisis aggravated by providers denying care for fear that their treatment will contravene state criminal law and lead to prosecution.⁴² No other practice of medicine bears witness to these types of denials of care based on state restrictions and ideological interference.

The Fifth Circuit’s order would exacerbate these adverse health outcomes by limiting access to the most common method of early abortion.⁴³ The partial stay also creates additional confusion on top of the post-*Dobbs* uncertainty surrounding the

³⁹ *Id.* at 9-10.

⁴⁰ Rosemary Westwood, *Bleeding and in Pain, She Couldn’t Get 2 Louisiana ERs to Answer: Is It a Miscarriage?*, WGPU (Dec. 29, 2022), <https://news.wgcu.org/2022-12-29/bleeding-and-in-pain-she-couldnt-get-2-louisiana-ers-to-answer-is-it-a-miscarriage>.

⁴¹ See Jessica Beaman et al., *Medication to Manage Abortion and Miscarriage*, 35 J. Gen. Intern. Med. 2398, 2398 (2020) (“Thus, for both medication abortion and medical management of early miscarriage, the standard of care is to provide oral mifepristone followed by misoprostol tablets.”).

⁴² See, e.g., Westwood, *supra* note 40.

⁴³ Rachel K. Jones et al., *Medication Abortion Now Accounts for More Than Half of All US Abortions*, Guttmacher Inst. (Feb. 24, 2022), <https://www.guttmacher.org/article/2022/02/medication-abortion-now-accounts-more-half-all-us-abortions>.

legality of different forms of reproductive health care. As a result, childbearing individuals may have to turn to procedural abortion, which is more invasive, may require extensive travel to obtain, has longer wait times, and is often much more expensive. Alternatively, affected individuals would have to seek other methods of medication abortion or travel to find a distributing physician, even though the FDA-approved conditions of use provide for the most accessible method of medication abortion in the United States.

These health risks, as well as financial and logistical challenges, would disproportionately affect individuals already facing systemic barriers to health care, who could be forced to choose amongst a more costly procedural abortion, costly travel and an unwanted pregnancy.⁴⁴ These particularly vulnerable groups may include low-income individuals, people of color, young people and those residing in rural areas.⁴⁵ Medication abortion using mifepristone is an important means for vulnerable groups to access medical care without having to bear the cost of long-distance travel to find access to procedural abortion and the difficulties associated

⁴⁴ See Katherine O’Connell White, *POV: Overturning Roe v. Wade Will Worsen Health Inequities in All Reproductive Care*, BU Today (June 24, 2022), <https://www.bu.edu/articles/2022/overturning-roe-v-wade-will-worsen-health-inequities/>.

⁴⁵ See generally Eugene Declercq et al., *The U.S. Maternal Health Divide: The Limited Maternal Health Services and Worse Outcomes of States Proposing New Abortion Restrictions*, Commonwealth Fund (Dec. 14, 2022), <https://www.commonwealthfund.org/publications/issue-briefs/2022/dec/us-maternal-health-divide-limited-services-worse-outcomes>; see also Rosalyn Schroeder et al., *Trends in Abortion Care in the United States, 2017-2021*, *Advancing New Standards in Reprod. Health*, U.C.S.F. (2022).

with getting time off or finding child care.⁴⁶ By curtailing access to the most common method of medication abortion, the Fifth Circuit’s order erects additional barriers to health care for vulnerable populations.

Reduced abortion access is also associated with higher rates of poverty, and lower educational attainment for both children and parents.⁴⁷ *The Turnaway Study* conducted at the University of California, San Francisco found that being denied an abortion was associated with increased economic insecurity and household poverty for both the mother and children born as a result of abortion denial.⁴⁸

The limited availability of mifepristone will have an especially acute impact on Black maternal health. In 2021, the overall maternal mortality rate shot up by nearly 40 percent,⁴⁹ and the maternal mortality rate for Black women was especially high, at 69.9 deaths per 100,000 live births—1.3 times higher than it was in 2020, and 2.6

⁴⁶ See Karen Brooks Harper, *Wealth Will Now Largely Determine Which Texans Can Access Abortion*, Tex. Trib. (June 24, 2022), <https://www.texastribune.org/2022/06/24/texas-abortion-costs/> (“About 73% of the people who call Fund Texas Choice for help with travel expenses are Black, Indigenous, Hispanic and Asian”); *id.* (“[T]hose working in wage-based jobs with no paid time off”); Chantel Boyens et al., *Access to Paid Leave Is Lowest Among Workers with the Greatest Needs 2*, Urban Inst. (July 2022).

⁴⁷ Diana Greene Foster et al., *Socioeconomic Outcomes of Women Who Receive and Women Who Are Denied Wanted Abortions in the United States*, 108 Am. J. Pub. Health 407, 412 (2018).

⁴⁸ See Diana Greene Foster, *The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having—or Being Denied—an Abortion* (2020).

⁴⁹ Donna L. Hoyert, *Maternal Mortality Rates in the United States, 2021*, CDC (Mar. 16, 2023), <https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.htm>.

times higher than the rate for white women.⁵⁰ In 2020, maternal death rates were 62 percent higher in abortion-restriction states than in abortion-access states.⁵¹ From 2018 to 2020, the maternal mortality rate increased nearly twice as fast in states with abortion restrictions than in states without them.⁵² Additional restrictions on access to medication abortion threaten to further increase the maternal mortality rate—an issue disproportionately affecting Black women—and exacerbate an already grave Black maternal health crisis.⁵³

The Fifth Circuit’s order will further restrict abortion access, exacerbating the harmful effects of existing limitations. Just as *Dobbs* upended abortion access and led to chaos following the decision, a stay of mifepristone’s current conditions of use will further narrow options for care.

⁵⁰ *Id.*; Donna L. Hoyert, *Maternal Mortality Rates in the United States, 2020*, CDC (Feb. 23, 2022), <https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2020/maternal-mortality-rates-2020.htm>.

⁵¹ Declercq et al., *supra* note 45, at Exhibit 4.

⁵² *Id.*

⁵³ *See id.* at Conclusion.

CONCLUSION

For the foregoing reasons, *Amici* Members of Congress respectfully request that this Court grant the applications to stay the district court's order and also grant an immediate administrative stay while it considers the applications.

Respectfully submitted,

Boris Bershteyn
Counsel of Record
One Manhattan West
New York, NY 10001
(212) 735-3000
boris.bershteyn@probonolaw.com

William A. McConagha
Jennifer L. Bragg
Keyawna Griffith
1414 New York Ave NW
Washington, DC 20005

April 14, 2023

APPENDIX

List of Amici Curiae

MEMBERS OF CONGRESS

50 United States Senators

Majority Leader Charles E. Schumer

Sen. Patty Murray

Sen. Bernard Sanders

Sen. Richard J. Durbin

Sen. Richard Blumenthal

Sen. Tammy Baldwin

Sen. Michael F. Bennet

Sen. Cory A. Booker

Sen. Sherrod Brown

Sen. Maria Cantwell

Sen. Benjamin L. Cardin

Sen. Thomas R. Carper

Sen. Robert P. Casey, Jr.

Sen. Christopher A. Coons

Sen. Catherine Cortez Masto

Sen. Tammy Duckworth

Sen. Dianne Feinstein

Sen. John Fetterman

Sen. Kirsten Gillibrand
Sen. Margaret Wood Hassan
Sen. Martin Heinrich
Sen. John W. Hickenlooper
Sen. Mazie Hirono
Sen. Tim Kaine
Sen. Mark Kelly
Sen. Angus S. King, Jr.
Sen. Amy Klobuchar
Sen. Ben Ray Luján
Sen. Edward J. Markey
Sen. Robert Menendez
Sen. Jeffrey A. Merkley
Sen. Christopher S. Murphy
Sen. Jon Ossoff
Sen. Alex Padilla
Sen. Gary C. Peters
Sen. Jack Reed
Sen. Jacky Rosen
Sen. Brian Schatz
Sen. Jeanne Shaheen
Sen. Kyrsten Sinema

Sen. Tina Smith

Sen. Debbie Stabenow

Sen. Jon Tester

Sen. Chris Van Hollen

Sen. Mark Warner

Sen. Raphael Warnock

Sen. Elizabeth Warren

Sen. Peter Welch

Sen. Sheldon Whitehouse

Sen. Ron Wyden

**203 Members of the
United States House of Representatives**

Minority Leader Hakeem Jeffries

Rep. Katherine Clark

Rep. Frank Pallone, Jr.

Rep. Jerrold Nadler

Rep. Diana DeGette

Rep. Barbara Lee

Rep. Alma S. Adams, Ph.D.

Rep. Pete Aguilar

Rep. Colin Allred

Rep. Jake Auchincloss

Rep. Becca Balint

Rep. Nanette Diaz Barragán

Rep. Joyce Beatty

Rep. Ami Bera, M.D.

Rep. Donald S. Beyer Jr.

Rep. Sanford Bishop

Rep. Earl Blumenauer

Rep. Lisa Blunt Rochester

Rep. Suzanne Bonamici

Rep. Jamaal Bowman, Ed.D.

Rep. Brendan Boyle

Rep. Shontel Brown
Rep. Julia Brownley
Rep. Nikki Budzinski
Rep. Cori Bush
Rep. Yadira Caraveo, M.D.
Rep. Salud Carbajal
Rep. Tony Cárdenas
Rep. Troy A. Carter, Sr.
Rep. Matt Cartwright
Rep. Greg Casar
Rep. Ed Case
Rep. Sean Casten
Rep. Kathy Castor
Rep. Joaquin Castro
Rep. Sheila Cherfilus-McCormick
Rep. Judy Chu
Rep. David N. Cicilline
Rep. Yvette D. Clarke
Rep. Emanuel Cleaver
Rep. James E. Clyburn
Rep. Steve Cohen
Rep. Gerald E. Connolly

Rep. J. Luis Correa
Rep. Joe Courtney
Rep. Angie Craig
Rep. Jasmine Crockett
Rep. Jason Crow
Rep. Sharice L. Davids
Rep. Danny K. Davis
Rep. Madeleine Dean
Rep. Rosa L. DeLauro
Rep. Suzan K. DelBene
Rep. Chris Deluzio
Rep. Mark DeSaulnier
Rep. Debbie Dingell
Rep. Lloyd Doggett
Rep. Veronica Escobar
Rep. Anna G. Eshoo
Rep. Adriano Espaillat
Rep. Dwight Evans
Rep. Lizzie Fletcher
Rep. Bill Foster
Rep. Valerie Foushee
Rep. Lois Frankel

Rep. Maxwell Alejandro Frost

Rep. Ruben Gallego

Rep. John Garamendi

Rep. Jesús G. “Chuy” García

Rep. Robert Garcia

Rep. Sylvia Garcia

Rep. Marie Gluesenkamp Perez

Rep. Dan Goldman

Rep. Jimmy Gomez

Rep. Josh Gottheimer

Rep. Al Green

Rep. Raúl M. Grijalva

Rep. Jahana Hayes

Rep. Brian Higgins

Rep. Jim Himes

Del. Eleanor Holmes Norton

Rep. Steven Horsford

Rep. Chrissy Houlahan

Rep. Steny H. Hoyer

Rep. Val Hoyle

Rep. Jared Huffman

Rep. Glenn Ivey

Rep. Sheila Jackson Lee

Rep. Sara Jacobs

Rep. Jeff Jackson

Rep. Pramila Jayapal

Rep. Henry C. "Hank" Johnson, Jr.

Rep. Sydney Kamlager-Dove

Rep. Marcy Kaptur

Rep. William R. Keating

Rep. Robin L. Kelly

Rep. Ro Khanna

Rep. Daniel T. Kildee

Rep. Derek Kilmer

Rep. Andy Kim

Rep. Raja Krishnamoorthi

Rep. Ann McLane Kuster

Rep. Greg Landsman

Rep. John B. Larson

Rep. Susie Lee

Rep. Summer Lee

Rep. Teresa Leger Fernandez

Rep. Mike Levin

Rep. Ted Lieu

Rep. Zoe Lofgren
Rep. Stephen Lynch
Rep. Seth Magaziner
Rep. Kathy Manning
Rep. Doris Matsui
Rep. Lucy McBath
Rep. Jennifer McClellan
Rep. Betty McCollum
Rep. Morgan McGarvey
Rep. James P. McGovern
Rep. Gregory Meeks
Rep. Robert Menendez
Rep. Grace Meng
Rep. Kweisi Mfume
Rep. Gwen Moore
Rep. Joseph Morelle
Rep. Jared Moskowitz
Rep. Seth Moulton
Rep. Kevin Mullin
Rep. Grace F. Napolitano
Rep. Richard E. Neal
Rep. Joe Neguse

Rep. Wiley Nickel
Rep. Donald Norcross
Rep. Alexandria Ocasio-Cortez
Rep. Ilhan Omar
Rep. Jimmy Panetta
Rep. Chris Pappas
Rep. Bill Pascrell
Rep. Donald M. Payne Jr.
Rep. Nancy Pelosi
Rep. Mary Peltola
Rep. Scott Peters
Rep. Brittany Pettersen
Rep. Dean Phillips
Rep. Chellie Pingree
Del. Stacey E. Plaskett
Rep. Mark Pocan
Rep. Katie Porter
Rep. Ayanna Pressley
Rep. Mike Quigley
Rep. Delia Ramirez
Rep. Jamie Raskin
Rep. Deborah K. Ross

Rep. Raul Ruiz, M.D.

Rep. C.A. Dutch Ruppersberger

Rep. Patrick Ryan

Del. Gregorio Kilili Camacho Sablan

Rep. Andrea Salinas

Rep. Linda T. Sánchez

Rep. John P. Sarbanes

Rep. Mary Gay Scanlon

Rep. Jan Schakowsky

Rep. Adam Schiff

Rep. Bradley S. Schneider

Rep. Hillary Scholten

Rep. Kim Schrier, M.D.

Rep. David Scott

Rep. Robert C. “Bobby” Scott

Rep. Terri A. Sewell

Rep. Brad Sherman

Rep. Mikie Sherrill

Rep. Elissa Slotkin

Rep. Adam Smith

Rep. Eric Sorensen

Rep. Darren Soto

Rep. Abigail Spanberger
Rep. Melanie Stansbury
Rep. Greg Stanton
Rep. Haley Stevens
Rep. Marilyn Strickland
Rep. Eric Swalwell
Rep. Emilia Sykes
Rep. Mark Takano
Rep. Mike Thompson
Rep. Dina Titus
Rep. Rashida Tlaib
Rep. Jill Tokuda
Rep. Paul Tonko
Rep. Ritchie Torres
Rep. Norma J. Torres
Rep. Lori Trahan
Rep. David Trone
Rep. Lauren Underwood
Rep. Gabe Vasquez
Rep. Marc A. Veasey
Rep. Nydia M. Velázquez
Rep. Debbie Wasserman Schultz

Rep. Maxine Waters

Rep. Bonnie Watson Coleman

Rep. Jennifer Wexton

Rep. Susan Wild

Rep. Nikema Williams

Rep. Frederica S. Wilson